Please login to the form below
ICS
This page shows the latest ICS news and features for those working in and with pharma, biotech and healthcare.
Novartis reveals full phase 3 results for Enerzair Breezhaler
and a high dose of an inhaled corticosteroid (ICS), who had experienced one or more asthma exacerbations in the previous year. ... symptoms despite receiving a LABA/ICS, which is the standard of care,” said Huib Kerstjens, head of the Department of
Latest news
-
AZ builds case for its COPD triple as it chases GSK’s Trelegy
Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s
-
Sanofi's Dupixent gains asthma approval in Europe
inflammation. However, Dupixent can only be used in this setting when patients have used at least one other maintenance treatment, along with high dose inhaled corticosteroid (ICS).
-
AZ prepares to file COPD triple, taking on rival GSK
The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –
-
AZ rival to GSK’s COPD drug Anoro fails head-to-head test
The real battleground between the two companies is expected to be three-drug combinations for COPD, with an inhaled corticosteroid (ICS) added to the LAMA/LABA duo.
-
AZ’s COPD triple data sets up market clash with GSK
on LABA vilanterol, LAMA umeclidinium and ICS fluticasone furoate - in the US and Europe last year.
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
GSK forges ahead with its dynamic COPD and asthma portfolio
For instance, in the UK, US, Canada and Spain, the first treatment was an ICS/LABA, such Seretide or Symbicort, while in Germany it was a bronchodilator.
-
The roaring ‘20s and Generation Z
For instance, the draft NHS Standard Contract 2020/21, published in December 2019 will see NHS Trusts and CCGs being contractually obliged to work collectively as a single local ICS system, ... Over the next five years at least, campaigns and messaging
-
NHS regional footprints
CCGs in action. In Nottinghamshire, six CCGs have joined forces to lead the strategic development of integrated care within the geographical area originally allocated to the Nottinghamshire ICS.
-
Deal Watch table for August 2014
600. TARIS Biomedical/ Allergan. Company acquisition. LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Delivering true value: what does it mean for KAM in cancer care?
The real challenge of working with these new ICS accounts and other integrated care organisations is very much about teamwork.
-
How will the Tories’ historic win shape the NHS?
Integrated care. The Tories’ win has provided assurance that there will be 100 percent Integrated Care System (ICS) coverage across England by April 2021, as promised in the Long-term Plan. ... We wait to see if it will mean a growth in CCG and ICS
-
2019: A pivotal year for the NHS
Structure. The Long-term Plan stated that, by April 2021, all areas of England will be covered by an Integrated Care System (ICS), with typically just one Clinical Commissioning Group (CCG) ... It means that hospitals and CCGs must now work together to
-
Early diagnosis underpins NHS cancer strategy
The Cancer Alliances will advise Sustainability and Transformation Partnership (STP) and Integrated Care System (ICS) board members on cancer services and help to ensure that local cancer strategies are delivered.
-
What role for pharma in helping to deliver integrated care?
Phil explained how Dorset ICS runs “a family budgeting system”, where money has already moved from one organisation to another to achieve balance across the system. ... To hear more from Dr Phil Richardson, of Dorset ICS, regarding integrated care
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Keytruda doubles five-year survival rate in NSCLC
- FDA approves Roche’s Actemra COVID-19 trial
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
